Memphasys (ASX:MEM)
ASX announcement history & article coverage
Transparent by design.
Announcments by Memphasys (ASX:MEM) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification regarding unquoted securities - MEM
Quarterly Activities/Appendix 4C Cash Flow Report
Memphasys reports record revenue and expands Felix commercial rollout with A$3.5m funding
Initial Director's Interest Notice
Proposed issue of securities - MEM
Memphasys receives A$3.5 million from Peters Investments
Memphasys secures A$3.5 million funding as Felix repeat orders accelerate
Potential Expedited FDA Pathway to US IVF Market
Memphasys identifies potential faster FDA pathway for Felix IVF system
Change of Director's Interest Notice
Notification regarding unquoted securities - MEM
Notification regarding unquoted securities - MEM
Application for quotation of securities - MEM
Memphasys Secures European Felix Agreement
Memphasys signs A$674,000 Felix distribution deal across three European markets
Memphasys Investor Webinar Presentation - September 2026
Investor Webinar Invite
Felix Registration Achieved in Turkey, Sales Commence
Memphasys launches Felix™ System commercial sales in Turkey following product registration
Notification of cessation of securities - MEM
EUR526,500 Nordic Agreement Expands Felix European Footprint
Memphasys expands Felix™ System into five Nordic countries with €526,500 commercial agreement
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Memphasys reports FY2026 revenue surge, narrows net loss, advances Felix™ commercialisation
Felix Early Thai FDA Approval, Commercial Launch Accelerates
Memphasys secures early Thai FDA approval for Felix™ System, activating exclusive distribution deal with IVF Envimed
Results of General Meeting
Felix Registration Achieved in Vietnam and Cartridge Order
Memphasys secures Vietnam registration for Felix™ System, triggers first 600-cartridge commercial order
Pivotal Felix Study Receives First Scientific Presentation
European Commercial Roll-out continues with Poland Agreement
Memphasys Secures Exclusive Felix™ Commercialisation Deal in Poland Worth A$350,000
Proposed issue of securities - MEM
Notice of General Meeting/Proxy Form